Articles published by Quiver Bioscience

Quiver Bioscience Receives Strategic Investment From the Porta Family to Advance UBE3A ASO Therapeutic Program for Dup15q Syndrome

April 13, 2026

From Quiver Bioscience

Via Business Wire

Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies

February 23, 2026

From Quiver Bioscience

Via Business Wire

Quiver Bioscience Secures Non-Dilutive Funding to Enhance CNS Genetic Medicine Drug Discovery Platform Capabilities and Advance Powerful AI/ML-Based In Vitro / In Silico Predictor of CNS Drug Safety

July 01, 2025

From Quiver Bioscience

Via Business Wire

Quiver Bioscience Appoints Graham Dempsey, PhD as Chief Executive Officer to Lead Scaling of AI-Driven CNS Platform and Advance Lead Program into the Clinic

June 16, 2025

From Quiver Bioscience

Via Business Wire

Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome

May 15, 2025

From Quiver Bioscience

Via Business Wire

Quiver Bioscience Announces Collaboration with the Dup15q Alliance to Advance Antisense Oligonucleotide Therapeutic Program

March 19, 2025

From Quiver Bioscience

Via Business Wire

Quiver Bioscience Announces Publication in Nature Communications Biology Detailing Application of the Quiver Genomic Positioning System (Brain GPS) to Therapeutic Discovery in Fragile X Syndrome using Human Models and Machine Learning Analysis

November 21, 2024

From Quiver Bioscience

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.